Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes
Status:
Completed
Trial end date:
2021-01-04
Target enrollment:
Participant gender:
Summary
The aim of the study is to compare the efficacy of low-dose dasiglucagon (Zealand Pharma,
Denmark) to oral carbohydrate consumption for prevention of s.c. insulin-induced hypoglycemia
in CSII- and MDI-treated people with type 1 diabetes.